A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction
← catalyst calendarNCT07657182 · readout in 1,569 d
Sponsored by Axogen Corporation (industry) · AXGN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
178estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-12 | estimated | When the study began enrolling |
| Primary completion | 2030-12-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Peripheral Nerve Injury
- Peripheral Nerve Discontinuity
- Mixed Peripheral Nerve Injury
- Motor Peripheral Nerve Injury
- Upper Extremity Nerve Injury
Interventions
- Biological: Avance Nerve Graft — also filed as Acellular nerve allograft-arwx
- Procedure: Sural nerve autograft
Primary outcomes
what the primary-completion date above is the date OFRecovery of motor function
measured Assessed at 24 months
Recovery of sensory function
measured Assessed at 24 months
Permalink · AXGN's whole pipeline · Catalyst calendar · Every registered study · What changed